Salute e Benessere

Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of…

Guided by a focused growth strategy centered on organic development, digital innovation, and deep customer partnerships, Siemens Healthineers shapes the future of advanced visualization (AV) by delivering scalable, integrated platforms that enhance diagnostic confidence and operational agility. The company's sustained investment in intelligent imaging software and adaptive workflow integration has enabled it to lead in a sector increasingly defined by complexity, interoperability, and…
PR Newswire
28/07/2025

Introducing Antigravity: The Future of Aerial Exploration and Storytelling

"Today, most drones are tools. With Antigravity, we're aiming higher," says BC Nie, Head of Marketing at Antigravity. "While others compete on specs, we've flipped the script, reimagining what a drone should be able to do. The result is something that empowers real emotion and enables experiences like freedom, creativity, and discovery for everyone." " Today, most drones are tools. With Antigravity, we're aiming higher, " says BC Nie, Head of Marketing at…
PR Newswire
28/07/2025

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the…

"The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for…
PR Newswire
28/07/2025

Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology…

Cumulus presented a poster titled, "Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale" which featured data confirming repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. Additionally, passive electroencephalography (EEG)…
PR Newswire
28/07/2025

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up…

Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value The company intends to establish a dedicated subsidiary, named “American BNB Strategy,” to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to $500 million in phases, targeting strategic, long-term investments in BNB coin...
Nasdaq GlobeNewswire
28/07/2025

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration…

· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] –Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class...
Nasdaq GlobeNewswire
28/07/2025

Cannabis Market worth $125.76 billion by 2030- Exclusive Report by…

Browse in-depth TOC on "Cannabis Market" Browse in-depth TOC on "Cannabis Market" 150– Tables 50– Figures 250– Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201768301 By application, nutraceutical & wellness form the fastest-growing segment in the global cannabis market. Nutraceutical and wellness-use cannabis includes cannabis-based products designed to support health, nutrition, and overall wellness without producing...
PR Newswire
28/07/2025

Dental Market to Grow at a CAGR of 6.3% from 2025 to 2032 | SkyQuest Technology…

Download Sample Pages of Research Overview: Download Sample Pages of Research Overview: https://www.skyquestt.com/sample-request/dental-market Dental Market Dynamics: The dental market has experienced significant growth owing to rising aesthetic consciousness, social media influence, and increasing disposable incomes have boosted demand for cosmetic dental procedures such as teeth whitening, veneers, and aligners. Patients prioritize appearance and smile makeovers, prompting...
PR Newswire
28/07/2025

Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced…

"Sniper G3 truly exemplifies our dedication to innovation driven by physician needs," said Michael Allen, President and CEO of Embolx. "We listened intently to our users and engineered a device that not only extends product longevity and improves performance, but also significantly enhances the ease of use, which translates directly to more efficient procedures. We are incredibly proud of Sniper G3 and its potential to set a new standard in embolization therapy." "…
PR Newswire
28/07/2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for…

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favorable tolerability profilePhase 1 clinical trial evaluating ZW251 in hepatocellular carcinoma (HCC) expected to be initiated in 2025 VANCOUVER, British Columbia, July28, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
Nasdaq GlobeNewswire
28/07/2025

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, July 28, 2025– Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) announced today that it has entered into an announcement agreement with Innosera ApS (the “Offeror”), a newly formed company controlled by Nordic Capital Fund XI 1and funds managed and advised by Permira...
Nasdaq GlobeNewswire
28/07/2025

Roche presents new insights in Alzheimer’s disease research across its…

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5%Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer’s disease featured, with initiation planned in 2025Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer’s disease, in people at high risk of cognitive declineNew real-world data...
Nasdaq GlobeNewswire
28/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential…
Actusnews Wire
25/07/2025

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

"We are excited about the Fast Track designation for SAP-001" says Dr. Wenfeng Miao, Shanton's CMO. "Refractory gout is a serious condition for which there are considerable unmet medical needs, requiring the development of new treatments. We are pleased to tap into the opportunity for faster regulatory reviews provided by this designation to speed up the availability of a much-needed solution for gout patients who do not respond to or cannot tolerate Standard-of-Care treatment…
PR Newswire
25/07/2025

Healthcare Analytical Testing Services Market worth $12.48 billion by 2030 with…

Additionally, emerging markets are expected to offer lucrative growth opportunities for market players during the forecast period. Additionally, emerging markets are expected to offer lucrative growth opportunities for market players during the forecast period. Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=108923833 Browse in-depth TOC on "Healthcare Analytical Testing Services Market" 421 - Tables 66 - Figures 408 - Pages By type, ...
PR Newswire
25/07/2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced...
Nasdaq GlobeNewswire
25/07/2025

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial…

"Building on the strong early launch of TRYNGOLZA in the U.S., the positive CHMP opinion advances our commitment to expand access to TRYNGOLZA globally," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "TRYNGOLZA has demonstrated significant reductions in triglycerides and substantial reductions in acute pancreatitis events with favourable safety and tolerability. With this robust clinical profile, combined with Sobi's deep commercial market expertise in FCS…
PR Newswire
25/07/2025

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of…

BiogenInc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE ®(zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with...
Nasdaq GlobeNewswire
25/07/2025

Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular…

EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys available to individuals living with DMD in the EURoche believes the benefit-risk remains positive in the ambulatory Duchenne populationElevidys is the first and only disease-modifying gene therapy for DMD...
Nasdaq GlobeNewswire
25/07/2025

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo®…

Pending European Commission (EC) approval, Alhemo ®will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors.This positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo ®reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B...
Nasdaq GlobeNewswire
25/07/2025

Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of…

Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol A Thousand Cuts, Sujata Setia, 2023, Urban Travel, Mithail Afrige Chowdhury, 2023, Cholesterol in the Liver, 2022, Steve GschmeissnerClick Here to download press images and captionsLONDON, July25, 2025(GLOBE NEWSWIRE) -- Wellcome’s 2025 Photography Prize celebrates three image makers whose work reveals...
Nasdaq GlobeNewswire
25/07/2025

PHNIX Launches Global Brand Upgrade and Two Flagship Products at Guangzhou…

During the summit, Mr. Hengyi Zhao, Vice Supervisor of the China Energy Conservation Association (CECA), awarded PHNIX the title of "International Heat Pump Brand," recognizing its leadership in sustainable innovation. A distribution partner from Germany also shared insights into PHNIX's exceptional product performance and strong reputation in Europe. During the summit, Mr. Hengyi Zhao, Vice Supervisor of the China Energy Conservation Association (CECA), awarded PHNIX the title of...
PR Newswire
25/07/2025

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The…

View original content:https://www.prnewswire.co.uk/news-releases/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-1-0-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint-302513822.html View original content: https://www.prnewswire.co.uk/news-releases/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-1-0-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint-302513822.html
PR Newswire
25/07/2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19…

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech...
Nasdaq GlobeNewswire
25/07/2025
Altri  Comunicati